EP 1608355 A2 20051228 - USE OF NEP-ASSOCIATED MOLECULES FOR TREATING NON-IMMUNOGENIC, NON-HYPERTENSIVE CIVILISATION DISEASES
Title (en)
USE OF NEP-ASSOCIATED MOLECULES FOR TREATING NON-IMMUNOGENIC, NON-HYPERTENSIVE CIVILISATION DISEASES
Title (de)
VERWENDUNG VON NEP-ASSOZIIERTEN MOLEK LEN ZUR BEHANDLUNG VON NICHTIMMUNOGENEN-NICHTHYPERTENSIVEN ZIVILISATIONSKRANKHEITEN
Title (fr)
UTILISATION DE MOLECULES ASSOCIEES A LA NEP POUR TRAITER DES TROUBLES COMPORTEMENTAUX NON IMMUNOGENES ET NON HYPERTENSIFS
Publication
Application
Priority
- DE 2004000491 W 20040308
- DE 10311984 A 20030312
Abstract (en)
[origin: DE10311984A1] Use of NEP (= neutral endopeptidase)-associated molecules (I) to prepare a composition for diagnosis, prophylaxis, (secondary) treatment, and/or monitoring of non-immunological, non-hypertensive diseases of civilization. Independent claims are also included for: (1) use of NEP-modified systems for investigation and/or development of agents for diagnosis, prophylaxis, (secondary) treatment, and/or monitoring of the specified diseases; (2) cosmetic treatment of eating disorders; (3) early diagnosis of concealed eating disorders; (4) identifying molecules that are deregulated by defective or increased NEP activity; (5) identifying NEP-target peptide hormones (X); (6) deregulated (X) obtained by method (5); (7) kit comprising modulators, stimulators, agonists, inhibitors, antagonists, recognition molecules, substrates and/or substrate inhibitors (Y) of NEP; (8) device that carries immobilized (Y); (9) non-human mammal that contains at least one NEP expression cassette; and (10) breeding non-human mammals that express NEP, peripherally or centrally. ACTIVITY : Anorectic; Nootropic; Neuroprotective. No details of tests for these activities are given. MECHANISM OF ACTION : Modulation of neutral endopeptidases.
IPC 1-7
A61K 31/165; A61K 31/554; A61K 35/78; A61P 3/00; A61P 3/04; A61P 25/28; A01K 67/027; A01K 67/02
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/165 (2006.01); A61K 31/554 (2006.01); A61K 35/74 (2006.01); A61K 36/00 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 25/28 (2006.01); C12N 15/85 (2006.01); C12Q 1/02 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/165 (2013.01); A61K 31/554 (2013.01); A61K 36/00 (2013.01); A61P 3/00 (2017.12); A61P 3/04 (2017.12); A61P 25/28 (2017.12); C12N 15/8509 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0312 (2013.01); A01K 2267/0356 (2013.01); A01K 2267/0362 (2013.01); G01N 2333/96486 (2013.01)
Citation (search report)
See references of WO 2004080448A2
Citation (examination)
- EP 0845264 A1 19980603 - FLACHSMANN AG EMIL [CH]
- FICHTER: "Die medikamentöse Behandlung von Anorexia und Bulimia nervosa", NERVENARZT, vol. 64, pages 21 - 35, XP008016116
- PRAGER: "Adipositas: Physiologie und Behandlungsmöglichkeiten", ACTA MED. AUSTRIACA, vol. 5, pages 94, XP009018826
- LUI ET AL: "Overexpression of Phex in Osteoblasts fails to rescue the Hyp Mouse Phenotype", THE JOUNRAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 5, - 2002, pages 3686 - 3697
- WAGENER A. ET AL: "Genetic, sex and diet effects on body weight and obesity in the Berlin Fat Mouse Inbred lines", PHYSIOL GENOMICS, vol. 27, 2006, pages 264 - 270
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
DE 10311984 A1 20040923; DE 10311984 A8 20050127; EP 1608355 A2 20051228; WO 2004080448 A2 20040923; WO 2004080448 A3 20041216
DOCDB simple family (application)
DE 10311984 A 20030312; DE 2004000491 W 20040308; EP 04718256 A 20040308